Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Clinical Investigation

• Publication date

  2000-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI9177PMID 10841521PMCID PMC300854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Professionals and amateurs

  2019cited by this paper
• Antigen-presenting cells. Experimental and clinical studies of dendritic cells.

  2000cited by this paper
• High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

  1999cited by this paper
• Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells.

  1999cited by this paper
• Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

  1999cited by this paper
• Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation.

  1999influential reference
• Costimulatory regulation of T cell function.

  1999cited by this paper
• Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.

  1999cited by this paper
• CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

  1999cited by this paper
• T cell memory against colon carcinoma is long-lived in the absence of antigen.

  1999cited by this paper
• Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

  1999cited by this paper
• Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.

  1999cited by this paper
• An innate sense of danger.

  1998cited by this paper
• T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

  1998cited by this paper
• The role of CD4+ T cell responses in antitumor immunity.

  1998cited by this paper
• Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy.

  1998cited by this paper
• Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.

  1998cited by this paper
• Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC.

  1998cited by this paper
• Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy.

  1998cited by this paper
• Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide.

  1998influential reference
• Activation of preexisting T cell clones by targeted interleukin 2 therapy.

  1998cited by this paper
• Melanoma‐associated antigens recognized by cytotoxic T lymphocytes

  1998cited by this paper
• Dendritic cells require maturation via CD40 to generate protective antitumor immunity.

  1998cited by this paper
• Immunocytokines: a promising approach to cancer immunotherapy.

  1998cited by this paper
• CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity.

  1998cited by this paper
• Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex.

  1998cited by this paper
• CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice.

  1998cited by this paper
• Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.

  1997cited by this paper
• Gene therapy for cancer: what have we done and where are we going?

  1997cited by this paper
• Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.

  1996cited by this paper
• An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.

  1996cited by this paper
• Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro

  1996cited by this paper
• Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.

  1996cited by this paper
• The SCID but Not the RAG-2 Gene Product Is Required for Sμ–Sε Heavy Chain Class Switching

  1996cited by this paper
• The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching.

  1996cited by this paper
• T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy

  1996cited by this paper
• Central tolerance of T cells.

  1995cited by this paper
• Chapter 15 Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotheraphy

  1994cited by this paper
• Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody.

  1994cited by this paper
• Tolerance, danger, and the extended family.

  1994cited by this paper
• A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice.

  1994cited by this paper
• Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy.

  1994cited by this paper
• Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40.

  1993cited by this paper
• A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells.

  1992cited by this paper

• Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing

  2025cites this paper
• ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice.

  2025cites this paper
• GD2-targeting therapy: a comparative analysis of approaches and promising directions

  2024cites this paper
• Utilizing Immunocytokines for Cancer Therapy

  2021cites this paper
• Tumor Microenvironment

  2020cites this paper
• Adaptive Immunity and the Tumor Microenvironment.

  2020cites this paper
• FC FUSION PROTEINS FOR ENHANCING THE IMMUNOGENCITY OF PROTEIN AND PEPTIDE ANTIGENS

  2017cites this paper
• United States Patent ( 10 ) Patent No . : US 8 , 926 , 973 B 2

  2017cites this paper
• Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

  2016cites this paper
• Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site

  2016cites this paper
• Tailoring the Treatment of Melanoma: Implications for Personalized Medicine

  2015influential citation
• Systemically transplanted human gingiva-derived mesenchymal stem cells contributing to bone tissue regeneration.

  2014cites this paper
• Myeloid-Derived Suppressor Cells Attenuate TH1 Development through IL-6 Production to Promote Tumor Progression

  2013cites this paper
• Agonistic anti-CD40 promotes early development and increases the incidence of severe thyroid epithelial cell hyperplasia (TEC H/P) in CD4−/− mice

  2013cites this paper
• induces complete protection against metastatic neuroblastoma Immunotherapy with a posttranscriptionally modified DNA vaccine

  2013cites this paper
• Innovative Cancer Vaccine Strategies Based on the Identification of Tumour-Associated Antigens

  2012cites this paper
• The role of CD4[superscript +]T cells during adoptive and active-specific cancer immunotherapy

  2012cites this paper
• Process development for the control of solubility of Affibody® molecules

  2011cites this paper
• Advances in lupus stemming from the parent-into-F1 model.

  2010cites this paper
• IL-4 Suppresses Very Late Antigen-4 Expression Which is Required for Therapeutic Th1 T-cell Trafficking Into Tumors

  2009cites this paper
• CTL-Promoting Effects of CD40 Stimulation Outweigh B Cell-Stimulatory Effects Resulting in B Cell Elimination and Disease Improvement in a Murine Model of Lupus1

  2008cites this paper
• Improvement in a Murine Model of Lupus Resulting in B Cell Elimination and Disease Outweigh B Cell-Stimulatory Effects CTL-Promoting Effects of CD 40 Stimulation

  2008cites this paper
• Identifikation und immunologische Charakterisierung von MHC-Klasse-II-Peptidepitopen in humanen Leukämie- und Lymphom-assoziierten Antigenen

  2006cites this paper
• Antibody targeted drugs as cancer therapeutics

  2006cites this paper
• Therapeutic efficacy of tumor-targeted IL2 in LTα−/− mice depends on conditioned T cells

  2006cites this paper
• Use of adenoviruses encoding CD40L or IL‐2 against B cell lymphoma

  2004cites this paper
• Technology evaluation: EMD-273063, EMD Lexigen.

  2004cites this paper
• Suppression of Hepatocellular Carcinoma Growth via Oral Immune Regulation towards Tumor-Associated Antigens Is Associated with Increased NKT and CD8+ Lymphocytes

  2004cites this paper
• Enhancement of antitumor response to sarcoma 45 in rats by combination of whole-body hyperthermia and interleukin-2.

  2004cites this paper
• Pox Viral Vaccines

  2004cites this paper
• Immunocytokines for Cancer Immunotherapy

  2004cites this paper
• Cell Responses + and CD8 CD40 and IL-2: Coordination of Dendritic Administration of Agonistic Antibodies to Synergistic Anti-Tumor Responses After

  2003cites this paper
• Native and recombinant interleukin-2, two functionally distinct molecules.

  2003cites this paper
• Immunotherapy of malignant melanoma.

  2003cites this paper
• Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma.

  2003cites this paper
• Immunocytokines: amplification of anti-cancer immunity

  2003cites this paper
• Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses 1

  2003cites this paper
• Skin Immunity And Melanoma Development

  2003cites this paper
• CD40 Ligation in the Presence of Self-Reactive CD8 T Cells Leads to Severe Immunopathology1

  2002cites this paper
• Advances in Brief Expression of a “ Self-” Antigen by Human Tumor Cells Enhances Tumor Antigen-specific CD 4 T-Cell Function

  2002cites this paper
• Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus.

  2002cites this paper
• A novel syngeneic murine model for thoracic neuroblastoma obtained by intramediastinal injection of tumor cells.

  2002cites this paper
• Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.

  2002cites this paper
• Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity.

  2002cites this paper
• Immunopathology Self-Reactive CD 8 T Cells Leads to Severe CD 40 Ligation in the Presence of

  2002cites this paper
• Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice.

  2001cites this paper
• In situ cytokine therapy: redistribution of clonally expanded T cells

  2001cites this paper
• Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.

  2001cites this paper
• An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice.

  2001cites this paper